Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
T Yoshida, K Yamada, K Azuma, A Kawahara, H Abe… - Medical oncology, 2013 - Springer
Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of
the epidermal growth factor receptor gene (EGFR-mt). These agents are considered to act
on EGFR through the same mechanism. However, the efficacy of these agents against
EGFR wild-type (-wt) NSCLC remains unclear, and the frequency of adverse events (AEs)
appears to differ between them at each approved dose. Here, we conducted a retrospective …
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of
the epidermal growth factor receptor gene (EGFR-mt). These agents are considered to act
on EGFR through the same mechanism. However, the efficacy of these agents against
EGFR wild-type (-wt) NSCLC remains unclear, and the frequency of adverse events (AEs)
appears to differ between them at each approved dose. Here, we conducted a retrospective …
以上显示的是最相近的搜索结果。 查看全部搜索结果